Homephotos Newsmarket Newsstocks News

    COVID-19 resilient 2.0 portfolio: IIFL Securities lists 9 stocks with up to 28% upside

    COVID-19 resilient 2.0 portfolio: IIFL Securities lists 9 stocks with up to 28% upside

    COVID-19 resilient 2.0 portfolio: IIFL Securities lists 9 stocks with up to 28% upside
    Profile image

    By Pranati Deva   IST (Published)

    Switch to Slide Show

    SUMMARY

    The second wave of COVID has been proving to be more disastrous than the first and many economic and health indicators are already pointing towards a downward revision in the GDP forecast. In such a scenario, brokerage house IIFL Securities suggest investing in the COVID resilient sectors. Sectors like Healthcare, Pharma, Diagnostic & select FMCG will continue to thrive during the FY22, it added. For FY21, it has built and recommended a 'Covid Resilient Portfolio' considering valuations and taking a bottom-up approach in the light of sharp rally in broader markets. Aided by the increased global liquidity and defensive COVID resilience nature of the portfolio, it expects very limited downside risk for these stocks. Here's the list:

    paracetamol medicines drugs pharma pharceuticals
    1 / 9

    Cipla: The brokerage has a 'buy' call on the stock with a target at Rs 1,050 per share, indicating a 15 percent upside to the stock. IIFL expects Cipla to register an FY23E EPS of 15 percent to factor in the Revlimid launch.

    2 / 9

    Metropolis Healthcare: The brokerage has a 'buy' call on the stock with a target at Rs 2,880 per share, indicating a 21 percent upside to the stock. IIFL believes Metropolis is well-positioned to sustain its B2C growth momentum, as two-thirds of its expanded service network is relatively young. It sees a 21 percent revenue and 20 percent EPS CAGR for Metropolis over FY21-23.

    3 / 9

    JB Chemicals: The brokerage has a 'buy' call on the stock with a target at Rs 1,680 per share, indicating a 17 percent upside to the stock. IIFL expects a return on invested capital (post-tax) to improve to 36 percent by FY23E and strong FCF generation to sustain.

    4 / 9

    Apollo Hospitals: The brokerage has a 'buy' call on the stock with a target at Rs 3,204 per share, indicating an 11 percent upside to the stock. IIFL noted that Apollo’s overall hospital occupancies improved to 63 percent in Q3FY21 from 56 percent in Q2FY21. Management indicated that occupancies should reach pre-COVID levels of 68-70 percent by Q1/Q2FY22, led by a pick-up in international patients, domestic travel and improving surgical volumes.

    Dr Lal Pathlabs
    5 / 9

    Dr Lal Pathlabs: The brokerage has a 'buy' call on the stock with a target at Rs 3,390 per share, indicating a 16 percent upside to the stock. With a dominant presence in North India, Dr Lal intends to deepen its penetration in North & East India through the addition of 12- 15 clinical labs annually. IIFL forecasts a 15 percent EPS CAGR for the firm over FY21-23 and expects strong near-term momentum in the COVID business.

    Dabur India
    6 / 9

    Dabur: The brokerage has a 'buy' call on the stock with a target at Rs 620 per share, indicating a 14 percent upside to the stock. As per IIFL, Dabur is ticking the right boxes in terms of riding the healthcare momentum and has accordingly stepped up the ad-spends intensity.

    7 / 9

    Thyrocare Tech: The brokerage has a 'buy' call on the stock with a target at Rs 1,250 per share, indicating an 18 percent upside to the stock. IIFL expects 12 percent revenue and 23 percent EPS CAGR for Thyrocare over FY21-23.

    SBI Life
    8 / 9

    SBI Life: The brokerage has a 'buy' call on the stock with a target at Rs 1,230 per share, indicating a 28 percent upside to the stock. IIFL expects India’s largest private life insurer on a retail APE basis to deliver strong growth in FY22, as its distribution channel comes back full force and the product mix stabilizes with a rise in the share of protection.

    9 / 9

    Cadila Healthcare: The brokerage has a 'buy' call on the stock with a target at Rs 670 per share, indicating a 15 percent upside to the stock. Cadila may continue to see the benefit of its COVID-drugs portfolio in FY22. Cadila’s Remdesivir is the lowest-priced variant in the Indian market and the management expects the strong double-digit growth in the Indian business to sustain for the next couple of quarters.

    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    arrow down

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng